Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.
Bischof A, Papinutto N, Keshavan A, Rajesh A, Kirkish G, Zhang X, Mallott JM, Asteggiano C, Sacco S, Gundel TJ, Zhao C, Stern WA, Caverzasi E, Zhou Y, Gomez R, Ragan NR, Santaniello A, Zhu AH, Juwono J, Bevan CJ, Bove RM, Crabtree E, Gelfand JM, Goodin DS, Graves JS, Green AJ, Oksenberg JR, Waubant E, Wilson MR, Zamvil SS; University of California, San Francisco MS-EPIC Team; Cree BAC, Hauser SL, Henry RG. Bischof A, et al. Among authors: goodin ds. Ann Neurol. 2022 Feb;91(2):268-281. doi: 10.1002/ana.26281. Epub 2022 Jan 4. Ann Neurol. 2022. PMID: 34878197 Free PMC article.
Neuromyelitis optica.
Cree BA, Goodin DS, Hauser SL. Cree BA, et al. Among authors: goodin ds. Semin Neurol. 2002 Jun;22(2):105-22. doi: 10.1055/s-2002-36534. Semin Neurol. 2002. PMID: 12524556 Review.
HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course.
Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, Swerdlin A, Pericak-Vance MA, Haines JL, Hauser SL; Multiple Sclerosis Genetics Group. Barcellos LF, et al. Among authors: goodin ds. Am J Hum Genet. 2003 Mar;72(3):710-6. doi: 10.1086/367781. Epub 2003 Jan 28. Am J Hum Genet. 2003. PMID: 12557126 Free PMC article.
The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS, et al. Neurology. 2003 Nov 25;61(10):1332-8. doi: 10.1212/01.wnl.0000095425.84407.39. Neurology. 2003. PMID: 14638950 Review.
Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans.
Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, Mignot E, Lin L, Goodin D, Erlich HA, Schmidt S, Thomson G, Reich DE, Pericak-Vance MA, Haines JL, Hauser SL. Oksenberg JR, et al. Am J Hum Genet. 2004 Jan;74(1):160-7. doi: 10.1086/380997. Epub 2003 Dec 10. Am J Hum Genet. 2004. PMID: 14669136 Free PMC article.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G; EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group. Schwid SR, et al. Arch Neurol. 2005 May;62(5):785-92. doi: 10.1001/archneur.62.5.785. Arch Neurol. 2005. PMID: 15883267 Clinical Trial.
194 results